Larazotide

立即咨询

Larazotide

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

258818-34-7

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

Larazotideis 是一种多肽，是具有口服活性的zonulin拮抗剂。Larazotide 对水痘带状疱疹病毒(VZV)具有抗病毒活性，对 OKA 和 07-1 株系的EC₅₀值分别为 44.14 和 59.06 μM。Larazotide 可用于乳糜泻和感染的研究。

生物活性

Larazotideis a peptide which is an orally activezonulinantagonist. Larazotide shows antiviral activity to varicella-zoster virus(VZV)withEC₅₀sof 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease andinfection^[1]^[2].

体外研究
(In Vitro)

Larazotide (1-100 μM; 5 d) affects Vero cell growth^[1].
Larazotide (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC₅₀s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively^[1].
Larazotide (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells^[2].
Larazotide (100 μM; 3 h) inhibits gliadin translocation across Caco-2 monolayers^[2].
Larazotide (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells^[2].

Cell Cytotoxicity Assay^[1]

Cell Line:	Vero cell line
Concentration:	1-100 μM
Incubation Time:	5 days
Result:	Inhibited Vero cell growth with an CC₅₀value of 82.5 μM.

体内研究
(In Vivo)

Larazotide (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice^[1].

Animal Model:	HLA-HCD4/DQ8 double transgenic mice^[2]
Dosage:	250 μg
Administration:	Intraperitoneal injection; 250 μg twice a week for 7 weeks
Result:	Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.

Clinical Trial

分子量

725.83

Formula

C₃₂H₅₅N₉O₁₀

CAS 号

258818-34-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.